ResMed
(NYSE: RMD)
today announced data from a number of clinical studies demonstrating the benefits of its positive airway pressure (PAP) therapy.
San Diego-based ResMed presented 13 new studies highlighting the use of PAP therapy for obstructive sleep apnea (OSA) at SLEEP 2024.
One study looked at adherence to PAP therapy and its link to hospital visits among patients with OSA and comorbid insomnia. Dr. Atul Malhotra of UCSD presented results that included lower hospitalizations and emergency room visits for patients who adhered to PAP therapy compared to those who demonstrated lower PAP adherence.
ResMed says hospitalizations went down by 31%, while ER visits fell 23%. The study concluded that PAP therapy, when adhered to, can improve health outcomes among patients with OSA and comorbid insomnia.
Another study evaluated women with OSA and found them more likely to suffer from depression and fall off PAP therapy. It looked at more than 345,000 adults with OSA who began PAP therapy. Of the nearly 17% with depression, more than a quarter (25.5%) were women.
In both women and men, individuals with depression had a greater burden of comorbidities. That includes obesity, hypertension, type 2 diabetes, coronary artery disease and heart failure. ResMed found lower adherence to PAP therapy among OSA patients with depression, particularly among women.
“The real-world evidence used in our clinical research continues to demonstrate the effectiveness of PAP therapy for treating OSA,” said Dr. Carlos M. Nunez, ResMed chief medical officer. “The studies presented at SLEEP 2024 expand our understanding of patients with sleep disorders by examining critical areas such as the effect of demographic factors like gender on sleep health. The body of knowledge we have created and are continually expanding with research partners who are highly respected in their fields helps ResMed and the medical community achieve the goal of helping people live their healthiest lives.”
Read on MDO: How ResMed designed its new AirFit F40 CPAP mask
